Fate Therapeutics Reports 3Q 2026 Revenue of $0 and EPS of ($0.25)
The company reported no collaboration revenue, compared with revenue a year earlier, after completing performance obligations under its Ono agreement in June. Net loss narrowed as lower research and administrative expenses were partly offset by reduced other income.
Fate Therapeutics reported no collaboration revenue in 3Q 2026, compared with revenue a year earlier, as performance obligations under its Ono agreement were completed in June. Net loss narrowed, with lower research and development and general and administrative expenses partly offset by reduced ot…